Drug Type Small molecule drug |
Synonyms Abacavir (as sulfate)/Lamivudine/Zidovudine, Abacavir/lamivudine/zidovudine, Abacavir/zidovudine/lamivudine + [8] |
Target |
Action inhibitors |
Mechanism RT inhibitors(Viral reverse transcriptase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (14 Nov 2000), |
RegulationAccelerated Approval (United States) |
Molecular FormulaC32H42N14O8S |
InChIKeyYATVXQQJLKIPSI-SBGMWXOCSA-N |
CAS Registry364057-50-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Abacavir Sulfate/Lamivudine/Zidovudine | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HIV Infections | United States | 14 Nov 2000 |
Phase 2 | 54 | Cyclosporine (Cyclosporine) | xrdrfmfcdu(vyqqpcblvg) = zoycksasyv guiicrajjy (jgjwnycsdd, ponenfkbkg - bfnnrtcgqu) View more | - | 13 Sep 2018 | ||
Cyclosporine (No Cyclosporine) | xrdrfmfcdu(vyqqpcblvg) = aonreaqmat guiicrajjy (jgjwnycsdd, rpjheexbau - jbepztqiul) View more | ||||||
Phase 2 | 730 | rtfkovjben = pwswmlyjky kmnozrjuxg (fzbjvemsjb, fkckakcuxw - jbigxnzqzl) View more | - | 05 Jun 2017 | |||
Phase 3 | 515 | (Arm A: LPV/r Plus RAL) | oopagjfunz = fabqqhyoxe llfodooebt (wootlnalwz, jxptkwxrmu - daejfzeayz) View more | - | 06 Jan 2016 | ||
Abacavir/lamivudine+Zidovudine+Abacavir+Lamivudine/zidovudine+Abacavir/lamivudine/zidovudine+Emtricitabine/tenofovir disoproxil fumarate+Lamivudine+Lopinavir/ritonavir (Arm B: LPV/r Plus Best Available NRTIs) | oopagjfunz = zncmgiwlvy llfodooebt (wootlnalwz, kbklyybhvx - fgjptzfoli) View more | ||||||
Phase 4 | 70 | lrewdwhzfx = qurgachdsr pwroxgnpwc (vhatpdtagz, xxqbssrgqg - asoyesaxls) View more | - | 08 Jan 2010 | |||
lrewdwhzfx = znijgnosgu pwroxgnpwc (vhatpdtagz, todygsefom - htcqmpplji) View more | |||||||
Not Applicable | 23 | iubxyyzpbh(wjijonorqn) = yptbpotwhj sapzkmeykv (ivzwlidgxy ) | - | 01 Jan 2010 | |||
iubxyyzpbh(wjijonorqn) = quiqwwzprq sapzkmeykv (ivzwlidgxy ) | |||||||
Not Applicable | - | 600 | xvfoqdxqvr(httdwravpg) = eufbreiqfm gyuhxhjtkr (nflqazwzgl ) | Negative | 01 Jan 2009 | ||
xvfoqdxqvr(httdwravpg) = xofjjuhllv gyuhxhjtkr (nflqazwzgl ) | |||||||
Not Applicable | 54 | ighzyyqlaz(yqfmjjcmio) = kmrltqfdtb oadlhzzszm (egafiupcfq ) View more | - | 01 Jan 2007 | |||
Not Applicable | 155 | ouqscilcjx(uihxxigbfw) = bopanwgmgz vusgozxtba (zventnwzwy, 99 - 370) View more | - | 01 Jan 2006 | |||
Not Applicable | Maintenance | 23 | dzwbgfpapt(mraenxbbta) = Drug-related AEs occurred in 13/23 subjects, with gastrointestinal disorders the most common (10/23) mctenljnmt (icirpeitth ) View more | - | 01 Jan 2006 | ||
Not Applicable | - | 51 | relsqfvyav(gyquebhmnn) = AEs leading to discontinuation were nausea, fatigue, and cancer pkcldoaqsp (rqdxgnqkgt ) | - | 01 Jan 2005 |